| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2d2967fdcc730ad36cb7be281fa96b4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3825fa97503eba1e41fc716350caa168
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9eb0cd5ac7f211d1ffa1f1601777fa71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_848098e0b79b61b483892be71b2cb27b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-205 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-616
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0007 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-46 |
| filingDate |
2004-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d0ed6366889a157c6c62d06cb849226
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e171613ffc546279601fd02a0b560ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4aee8241bd4e4009a8cfe2256535b0a |
| publicationDate |
2005-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2005065319-A2 |
| titleOfInvention |
Generally linear effervescent oral fentanyl dosage form and methods of administering |
| abstract |
Fentanyl containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than know oral formulation and have advantages in terms of cost and side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9744129-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009502761-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10736838-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10245228-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2006271870-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8298577-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8865211-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8865743-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010532745-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009522370-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10342762-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007009806-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10251834-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013049730-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10507180-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014145285-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7862832-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101497887-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2983719-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8778394-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8778393-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007009806-A3 |
| priorityDate |
2003-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |